异动解读 | ADMA Biologics季度业绩符合预期,却意外盘前大跌9.82%

异动解读
Aug 07

生物制药公司ADMA Biologics Inc(ADMA)今日盘前股价大跌9.82%,尽管公司最新公布的季度业绩基本符合市场预期。这一意外走势引发了投资者的广泛关注。

根据公司发布的财报,截至6月30日的季度调整后每股收益为14美分,与分析师预期一致,同时高于去年同期的13美分。营收同比增长13.8%,达到1.2198亿美元,略低于分析师预期的1.2267亿美元。公司报告的季度净收入为3422万美元。值得注意的是,ADMA Biologics的股价在本季度曾上涨4.1%,今年迄今为止更是上涨了10.6%。

尽管公司业绩总体表现不俗,但盘前大跌可能反映了投资者对未来增长前景的担忧。分析显示,过去三个月,分析师对该公司的平均盈利预期下降了约16%,这可能是导致股价下跌的一个重要因素。此外,虽然华尔街分析师对ADMA的平均评级仍为"买入",12个月目标价中位数为31.00美元,较之前交易日收盘价高出38.8%,但投资者似乎选择了更为谨慎的态度。这种反应可能也与近期股价涨幅较大有关,部分投资者可能选择获利了结,进一步加剧了股价的下跌。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10